Insights from genome‐wide association studies of progression in Parkinson's disease

Using an approach similar to that successful in Huntington’s disease, researchers at University College London, UK, have obtained risk scores for motor progression, cognitive progression, and composite (motor and cognitive) progression in patients with Parkinson’s disease (PD).

To do so they applied case-control, genome‐wide association studies (GWASs) to systematically collected clinical data from more than 3,000 PD patients in three large, longitudinal, prospective cohorts followed up for a mean of 4.2 years.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.